Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies
Cytosine arabinoside (ara-C) and etoposide (VP-16) display synergy in the laboratory. Twenty-six patients participated in a phase I study of high-dose ara-C in combination with VP-16. The dose of VP-16 was held constant at 50 mg/m2 as an intermittent infusion over 33 h; escalating doses of ara-C wer...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 1987-01, Vol.19 (3), p.250-252 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 252 |
|---|---|
| container_issue | 3 |
| container_start_page | 250 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 19 |
| creator | POWELL, B. L MUSS, H. B CRUZ, J. M SPURR, C. L CAPIZZI, R. L CAPONERA, M. E WHITE, D. R ZEKAN, P. J ATKINS, J. N JACKSON, D. V. JR RICHARDS, F. II CRAIG, J. B |
| description | Cytosine arabinoside (ara-C) and etoposide (VP-16) display synergy in the laboratory. Twenty-six patients participated in a phase I study of high-dose ara-C in combination with VP-16. The dose of VP-16 was held constant at 50 mg/m2 as an intermittent infusion over 33 h; escalating doses of ara-C were given as infusions during hours 9-12 and 21-24. Myelosuppression was the dose-limiting toxicity and occurred with doses considerably less than those expected from studies of the two drugs as single agents. The suggested initial doses for phase II trials with this schedule are 750 mg/m2 X 2 doses of ara-C and 50 mg/m2 of VP-16. Nonhematologic toxicity was minimal; therefore, further dose escalation is feasible in patients in whom myelosuppression is acceptable. |
| doi_str_mv | 10.1007/BF00252981 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00252981</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3581419</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-b65bfa9598e68fecd2726c1231209236365512ff125dce3c56e6f88d36cc43583</originalsourceid><addsrcrecordid>eNpFkEtLAzEUhYMotVY37oUsXAmjeU9mqcVqoaALXQ-ZPDqRNjNMUkv_vSktdXXPvefjwjkA3GL0iBEqn15mCBFOKonPwBgzSgokGT0HY0QZK3iJ2CW4ivEHIcQwpSMwolxihqsxMJ-tihbOYUwbs4Odg61ftoXp8lHvUhd9sFANqvEha5N1MNCmrj9sPsBeJW9DinDrUwuV-VVBWwPXauWXIWtv4zW4cGoV7c1xTsD37PVr-l4sPt7m0-dFoSnGqWgEb5yqeCWtkM5qQ0oiNCYUE1QRKqjgHBPnMOFGW6q5sMJJaajQmuVEdAIeDn_10MU4WFf3g1-rYVdjVO-bqv-byvDdAe43zdqaE3qsJvv3R19FrVZu2GeJJ0wSLktO6B_hYW_9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>POWELL, B. L ; MUSS, H. B ; CRUZ, J. M ; SPURR, C. L ; CAPIZZI, R. L ; CAPONERA, M. E ; WHITE, D. R ; ZEKAN, P. J ; ATKINS, J. N ; JACKSON, D. V. JR ; RICHARDS, F. II ; CRAIG, J. B</creator><creatorcontrib>POWELL, B. L ; MUSS, H. B ; CRUZ, J. M ; SPURR, C. L ; CAPIZZI, R. L ; CAPONERA, M. E ; WHITE, D. R ; ZEKAN, P. J ; ATKINS, J. N ; JACKSON, D. V. JR ; RICHARDS, F. II ; CRAIG, J. B</creatorcontrib><description>Cytosine arabinoside (ara-C) and etoposide (VP-16) display synergy in the laboratory. Twenty-six patients participated in a phase I study of high-dose ara-C in combination with VP-16. The dose of VP-16 was held constant at 50 mg/m2 as an intermittent infusion over 33 h; escalating doses of ara-C were given as infusions during hours 9-12 and 21-24. Myelosuppression was the dose-limiting toxicity and occurred with doses considerably less than those expected from studies of the two drugs as single agents. The suggested initial doses for phase II trials with this schedule are 750 mg/m2 X 2 doses of ara-C and 50 mg/m2 of VP-16. Nonhematologic toxicity was minimal; therefore, further dose escalation is feasible in patients in whom myelosuppression is acceptable.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/BF00252981</identifier><identifier>PMID: 3581419</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Adult ; Aged ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Chemotherapy ; Colonic Neoplasms - drug therapy ; Cytarabine - administration & dosage ; Drug Evaluation ; Etoposide - administration & dosage ; Female ; Genital Neoplasms, Female - drug therapy ; Head and Neck Neoplasms - drug therapy ; Hematologic Diseases - chemically induced ; Humans ; Kidney Neoplasms - drug therapy ; Lymphoma, Non-Hodgkin - drug therapy ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments</subject><ispartof>Cancer chemotherapy and pharmacology, 1987-01, Vol.19 (3), p.250-252</ispartof><rights>1987 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-b65bfa9598e68fecd2726c1231209236365512ff125dce3c56e6f88d36cc43583</citedby><cites>FETCH-LOGICAL-c311t-b65bfa9598e68fecd2726c1231209236365512ff125dce3c56e6f88d36cc43583</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=8258752$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3581419$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>POWELL, B. L</creatorcontrib><creatorcontrib>MUSS, H. B</creatorcontrib><creatorcontrib>CRUZ, J. M</creatorcontrib><creatorcontrib>SPURR, C. L</creatorcontrib><creatorcontrib>CAPIZZI, R. L</creatorcontrib><creatorcontrib>CAPONERA, M. E</creatorcontrib><creatorcontrib>WHITE, D. R</creatorcontrib><creatorcontrib>ZEKAN, P. J</creatorcontrib><creatorcontrib>ATKINS, J. N</creatorcontrib><creatorcontrib>JACKSON, D. V. JR</creatorcontrib><creatorcontrib>RICHARDS, F. II</creatorcontrib><creatorcontrib>CRAIG, J. B</creatorcontrib><title>Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><description>Cytosine arabinoside (ara-C) and etoposide (VP-16) display synergy in the laboratory. Twenty-six patients participated in a phase I study of high-dose ara-C in combination with VP-16. The dose of VP-16 was held constant at 50 mg/m2 as an intermittent infusion over 33 h; escalating doses of ara-C were given as infusions during hours 9-12 and 21-24. Myelosuppression was the dose-limiting toxicity and occurred with doses considerably less than those expected from studies of the two drugs as single agents. The suggested initial doses for phase II trials with this schedule are 750 mg/m2 X 2 doses of ara-C and 50 mg/m2 of VP-16. Nonhematologic toxicity was minimal; therefore, further dose escalation is feasible in patients in whom myelosuppression is acceptable.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Colonic Neoplasms - drug therapy</subject><subject>Cytarabine - administration & dosage</subject><subject>Drug Evaluation</subject><subject>Etoposide - administration & dosage</subject><subject>Female</subject><subject>Genital Neoplasms, Female - drug therapy</subject><subject>Head and Neck Neoplasms - drug therapy</subject><subject>Hematologic Diseases - chemically induced</subject><subject>Humans</subject><subject>Kidney Neoplasms - drug therapy</subject><subject>Lymphoma, Non-Hodgkin - drug therapy</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEtLAzEUhYMotVY37oUsXAmjeU9mqcVqoaALXQ-ZPDqRNjNMUkv_vSktdXXPvefjwjkA3GL0iBEqn15mCBFOKonPwBgzSgokGT0HY0QZK3iJ2CW4ivEHIcQwpSMwolxihqsxMJ-tihbOYUwbs4Odg61ftoXp8lHvUhd9sFANqvEha5N1MNCmrj9sPsBeJW9DinDrUwuV-VVBWwPXauWXIWtv4zW4cGoV7c1xTsD37PVr-l4sPt7m0-dFoSnGqWgEb5yqeCWtkM5qQ0oiNCYUE1QRKqjgHBPnMOFGW6q5sMJJaajQmuVEdAIeDn_10MU4WFf3g1-rYVdjVO-bqv-byvDdAe43zdqaE3qsJvv3R19FrVZu2GeJJ0wSLktO6B_hYW_9</recordid><startdate>19870101</startdate><enddate>19870101</enddate><creator>POWELL, B. L</creator><creator>MUSS, H. B</creator><creator>CRUZ, J. M</creator><creator>SPURR, C. L</creator><creator>CAPIZZI, R. L</creator><creator>CAPONERA, M. E</creator><creator>WHITE, D. R</creator><creator>ZEKAN, P. J</creator><creator>ATKINS, J. N</creator><creator>JACKSON, D. V. JR</creator><creator>RICHARDS, F. II</creator><creator>CRAIG, J. B</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19870101</creationdate><title>Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies</title><author>POWELL, B. L ; MUSS, H. B ; CRUZ, J. M ; SPURR, C. L ; CAPIZZI, R. L ; CAPONERA, M. E ; WHITE, D. R ; ZEKAN, P. J ; ATKINS, J. N ; JACKSON, D. V. JR ; RICHARDS, F. II ; CRAIG, J. B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-b65bfa9598e68fecd2726c1231209236365512ff125dce3c56e6f88d36cc43583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Colonic Neoplasms - drug therapy</topic><topic>Cytarabine - administration & dosage</topic><topic>Drug Evaluation</topic><topic>Etoposide - administration & dosage</topic><topic>Female</topic><topic>Genital Neoplasms, Female - drug therapy</topic><topic>Head and Neck Neoplasms - drug therapy</topic><topic>Hematologic Diseases - chemically induced</topic><topic>Humans</topic><topic>Kidney Neoplasms - drug therapy</topic><topic>Lymphoma, Non-Hodgkin - drug therapy</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>POWELL, B. L</creatorcontrib><creatorcontrib>MUSS, H. B</creatorcontrib><creatorcontrib>CRUZ, J. M</creatorcontrib><creatorcontrib>SPURR, C. L</creatorcontrib><creatorcontrib>CAPIZZI, R. L</creatorcontrib><creatorcontrib>CAPONERA, M. E</creatorcontrib><creatorcontrib>WHITE, D. R</creatorcontrib><creatorcontrib>ZEKAN, P. J</creatorcontrib><creatorcontrib>ATKINS, J. N</creatorcontrib><creatorcontrib>JACKSON, D. V. JR</creatorcontrib><creatorcontrib>RICHARDS, F. II</creatorcontrib><creatorcontrib>CRAIG, J. B</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>POWELL, B. L</au><au>MUSS, H. B</au><au>CRUZ, J. M</au><au>SPURR, C. L</au><au>CAPIZZI, R. L</au><au>CAPONERA, M. E</au><au>WHITE, D. R</au><au>ZEKAN, P. J</au><au>ATKINS, J. N</au><au>JACKSON, D. V. JR</au><au>RICHARDS, F. II</au><au>CRAIG, J. B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>1987-01-01</date><risdate>1987</risdate><volume>19</volume><issue>3</issue><spage>250</spage><epage>252</epage><pages>250-252</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>Cytosine arabinoside (ara-C) and etoposide (VP-16) display synergy in the laboratory. Twenty-six patients participated in a phase I study of high-dose ara-C in combination with VP-16. The dose of VP-16 was held constant at 50 mg/m2 as an intermittent infusion over 33 h; escalating doses of ara-C were given as infusions during hours 9-12 and 21-24. Myelosuppression was the dose-limiting toxicity and occurred with doses considerably less than those expected from studies of the two drugs as single agents. The suggested initial doses for phase II trials with this schedule are 750 mg/m2 X 2 doses of ara-C and 50 mg/m2 of VP-16. Nonhematologic toxicity was minimal; therefore, further dose escalation is feasible in patients in whom myelosuppression is acceptable.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>3581419</pmid><doi>10.1007/BF00252981</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 1987-01, Vol.19 (3), p.250-252 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_crossref_primary_10_1007_BF00252981 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Chemotherapy Colonic Neoplasms - drug therapy Cytarabine - administration & dosage Drug Evaluation Etoposide - administration & dosage Female Genital Neoplasms, Female - drug therapy Head and Neck Neoplasms - drug therapy Hematologic Diseases - chemically induced Humans Kidney Neoplasms - drug therapy Lymphoma, Non-Hodgkin - drug therapy Medical sciences Middle Aged Pharmacology. Drug treatments |
| title | Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T00%3A59%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20I%20study%20of%20high-dose%20cytosine%20arabinoside%20and%20etoposide%20in%20patients%20with%20advanced%20malignancies&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=POWELL,%20B.%20L&rft.date=1987-01-01&rft.volume=19&rft.issue=3&rft.spage=250&rft.epage=252&rft.pages=250-252&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/BF00252981&rft_dat=%3Cpubmed_cross%3E3581419%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/3581419&rfr_iscdi=true |